Goldman Sachs Bullish on Amicus Therapeutics (FOLD) Following Q3 2025 Results

With significant upside potential and hedge fund interest, Amicus Therapeutics, Inc. (NASDAQ:FOLD) secured a spot on our list of the 15 stocks set to explode in 2026.

On November 5, 2025, Goldman Sachs raised its price target on Amicus Therapeutics, Inc. (NASDAQ:FOLD) from $9 to $11, maintaining a “Neutral” rating.

The revision follows the company’s performance in the third quarter, marked by the first positive GAAP net income and solid revenue execution. With the expectation of sustained profitability, these outcomes reinforced the analyst’s confidence in Amicus Therapeutics, Inc.’s (NASDAQ:FOLD) full-year revenue outlook.

Prior to this revision, Amicus Therapeutics, Inc. (NASDAQ:FOLD) reported its Q3 2025 results on November 4, posting a 17% revenue surge to $169.1 million. With GAAP net income of $17.3 million, or $0.06 per share basic and diluted, the quarter marked the company’s milestone transition to GAAP profitability. Commenting on the company’s quarterly performance, CEO Bradley Campbell highlighted commercial momentum and steady clinical progress, including the on-track Phase 3 enrollment of DMX-200, as key drivers of long-term growth.

Looking ahead, Amicus Therapeutics, Inc.’s (NASDAQ:FOLD) management has reaffirmed its full-year revenue guidance and its target to exceed $1 billion in sales by 2028. Thus, it looks well-positioned for durable expansion, reinforcing investor optimism.

Amicus Therapeutics, Inc. (NASDAQ:FOLD), a global biotechnology company, develops and commercializes innovative medicines for patients living with rare diseases.

While we acknowledge the potential of FOLD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 7 Best Oil and Gas Penny Stocks to Buy According to Analysts and Billionaire Jacob Rothschild’s RIT Capital Partners: 9 Stocks with Huge Upside Potential.

Disclosure: None.